Hirokazu Ohsawa

Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors

Hiroshi Sootome, Hidenori Fujita, Kenjiro Ito et al. · Cancer Research · 2020 · 184 citations · Full text

TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations

Shinichi Hasako, Miki Terasaka, Naomi Abe et al. · Molecular Cancer Therapeutics · 2018 · 82 citations

Structures of the PKC-ι kinase domain in its ATP-bound and apo forms reveal defined structures of residues 533–551 in the C-terminal tail and their roles in ATP binding

Tetsuo Takimura, Kenji Kamata, Kazuhiro Fukasawa et al. · Acta Crystallographica Section D Biological Crystallography · 2010 · 49 citations

Protein Assembly, C-terminal Tail, Molecular Biology +20

Hydrocarbons with a homoconjugated polyene system and their monoepoxy derivatives: Sex attractants of geometrid and noctuid moths distributed in Japan

Tetsu Ando, Hirokazu Ohsawa, Tadahiro Ueno et al. · Journal of Chemical Ecology · 1993 · 44 citations

Natural Sciences, Entomology, Evolutionary Biology +7

Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use

Satoru Ito, Sachie Otsuki, Hirokazu Ohsawa et al. · ACS Medicinal Chemistry Letters · 2023 · 31 citations · Full text